
    
      Patients with seasonal grass pollen related rhinoconjunctivitis will be randomized to one of
      four treatment groups at 41 centres in Europe. Each treatment group will consist of
      approximately 150 patients and 150 patients will be randomized to a placebo group. The study
      will consist of a screening phase, a treatment phase and a variable maintenance period.
    
  